FDA approves Empagliflozin for heart failure despite contrary results

Published On 2022-03-03 13:15 GMT | Update On 2022-03-03 15:56 GMT

Trials are being conducted to prevent cardiac death, The US Food and Drug Administration (FDA) has approved an expanded heart failure (HF) indication for the SGLT2 inhibitor empagliflozin that now includes heart failure with mid-range or preserved left-ventricular ejection fraction despite several results not in favour of the drug. FDA used a cautionary language in using these drugs for treatment of heart failure.

Several trials like EMPEROR PRESERVED Trial, widely anticipated the use of Empagliflozin based on the landmark results of the trial and saw a significant 21% relative reduction of occurrence of heart failure. Similarly another trial PARAGON- HF Trial evaluated sacubitril/valsartan drug, it enrolled patients with Heart Failure and Left Ventricular Ejection Fraction. The trial was "negative" in that it saw no significant advantage to the drug for its primary clinical outcome.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

FDA approves Empagliflozin for heart failure despite contrary results

Similar News

Could Heart Attacks Be Caused by Bacteria? Study Provide Insights

Weight Loss Drugs May Lower Risk of Heart Failure Hospitalization and Death by 40 Percent: Study

Is Your Mental Health Putting Your Heart at Risk? Study Sheds Light

No Benefit of Beta Blockers in Certain Heart Attack Patients: REBOOT Trial Finds

Study Reveals Potassium-Rich Foods May Lower Irregular Heartbeat Risk

Study Reveals Daily Intake of Five Mushrooms May Reduce Alzheimer's and Heart Disease Risk

Depression And Schizophrenia Double Heart Disease And Mortality Risks: Lancet Report

How Dangerous Is Irregular Sleep for Heart Failure Survivors? Study Finds Out